Novo Nordisk sues Eli Lilly over GLP-1 advertising

What happened: On July 21, 2026, Novo Nordisk filed a lawsuit against Eli Lilly in the U.S. District Court, alleging deceptive advertising of Lilly's GLP-1 drugs, Zepbound and Mounjaro. Novo claims Lilly's advertising campaigns mislead consumers about the effectiveness of its own GLP-1 treatments, Wegovy and Ozempic.

Market impact: This lawsuit could disrupt the GLP-1 market, affecting both companies' drug sales. If Lilly's advertising is deemed deceptive, it could face penalties and reputation damage, potentially impacting its stock price. Conversely, if Novo's lawsuit is dismissed, it could boost Lilly's shares. The GLP-1 market, valued at over $20 billion, is a key growth driver for both companies.

What to watch next: On October 25, 2026, Lilly reports its Q3 earnings, which could provide insights into the impact of the lawsuit on its financials. Additionally, the court's decision on Novo's motion for a preliminary injunction, expected by year-end, will shape the narrative's next chapter. Lastly, any regulatory responses to the lawsuit's allegations could influence the GLP-1 market dynamics.